[Cost-effectiveness of consolidation treatments for acute myeloid leukemia in high-risk pediatric patients within the Colombian healthcare system].

INTRODUCTION Acute myeloid leukemia represents about 20% of leukemias in minors under 18 years old. At present, there are only two consolidation treatment alternatives: Chemotherapy and stem-cell transplantation. OBJECTIVE To evaluate the cost-effectiveness of unrelated and related hematopoietic stem cell transplantations, versus chemotherapy consolidation in pediatric patients with high-risk acute myeloid leukemia. MATERIALS AND METHODS A decision tree was constructed with life-years gained as the outcome. Costs and probabilities were extracted from the literature. Probabilistic sensitivity analyses and acceptability curves were computed. The cost-effectiveness threshold was three times the 2010 per capita gross domestic product. RESULTS When compared to consolidation chemotherapy cycles, related and unrelated hematopoietic stem-cell transplantation had incremental cost-effectiveness ratios of COP$ 9,226,421 (USD$ 4,820) and COP$ 6,544,116 (USD$ 3,419) respectively, which are lower than the per capita gross domestic product (COP$ 12,047,418, USD$ 6,294). Transplant proved to be cost-effective in 70% of the simulations and had a higher probability of the willingness to pay being over than COP$ 7,200,000 (USD$ 3,762). CONCLUSION In Colombia, related and unrelated hematopoietic stem-cell transplants are cost-effective alternatives to consolidation treatment for high-risk acute myeloid leukemia in pediatric patients.

[1]  A. Linares,et al.  Costo-efectividad consolidación de LMA pediátrica de riesgo intermedio en Colombia , 2013 .

[2]  L. Bravo,et al.  Descriptive epidemiology of childhood cancer in Cali , 2013, Colombia medica.

[3]  M. Shimoyama,et al.  Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission. , 2012, Clinical lymphoma, myeloma & leukemia.

[4]  M. Horowitz.  Does matched unrelated donor transplantation have the same outcome as matched sibling transplantation in unselected patients? , 2012, Best practice & research. Clinical haematology.

[5]  S. Bayliss,et al.  Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review. , 2010, Health technology assessment.

[6]  J. Dipersio,et al.  Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. , 2010, Blood.

[7]  K. Cornetta,et al.  Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia , 2010, Bone Marrow Transplantation.

[8]  Hisashi Sakamaki,et al.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. , 2009, JAMA.

[9]  A. Barrett,et al.  The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. , 2009, Blood.

[10]  D. Niederwieser,et al.  Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission , 2009, Leukemia.

[11]  R. Schlenk,et al.  HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  S. Feig,et al.  Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. , 2008, Blood.

[13]  J. Brophy,et al.  The cost-effectiveness of stem cell transplantations from unrelated donors in adult patients with acute leukemia. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  S. Feig,et al.  Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era , 2005, Leukemia.

[15]  T. Naoe,et al.  Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission , 2005, Cancer.

[16]  D. Reinhardt,et al.  Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Reinhardt,et al.  Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93 , 2004, Leukemia.

[18]  J. Bourhis,et al.  Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. , 2003, Blood.

[19]  S. Fröhling,et al.  Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial , 2003, Leukemia.

[20]  A. Kaufman,et al.  Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis , 2002, Bone Marrow Transplantation.

[21]  F. Berthold,et al.  Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .